Assembly Biosciences Inc
NASDAQ:ASMB

Watchlist Manager
Assembly Biosciences Inc Logo
Assembly Biosciences Inc
NASDAQ:ASMB
Watchlist
Price: 26.44 USD -3.92%
Market Cap: $418.3m

Operating Margin

-116.8%
Current
Improving
by 168%
vs 3-y average of -284.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116.8%
=
Operating Income
$-43.4m
/
Revenue
$37.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116.8%
=
Operating Income
$-43.4m
/
Revenue
$37.2m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Assembly Biosciences Inc
NASDAQ:ASMB
418.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-116.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Assembly Biosciences Inc
Glance View

Market Cap
418.3m USD
Industry
Biotechnology

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 102 full-time employees. The company went IPO on 2010-12-17. The firm is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The firm is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

ASMB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-116.8%
=
Operating Income
$-43.4m
/
Revenue
$37.2m
What is Assembly Biosciences Inc's current Operating Margin?

The current Operating Margin for Assembly Biosciences Inc is -116.8%, which is above its 3-year median of -284.8%.

How has Operating Margin changed over time?

Over the last 2 years, Assembly Biosciences Inc’s Operating Margin has increased from -902.5% to -116.8%. During this period, it reached a low of -902.5% on Dec 31, 2023 and a high of -116.8% on Oct 30, 2025.

Back to Top